Clinical Trial

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-01 -> 2027-05-17 2026-08-06
minor Completion pushed: 2026-07-01 -> 2027-05-17 2026-08-06
Trial Details
NCT Number NCT03346135
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Plasma Cell Myeloma, Secondary Amyloidosis
Enrollment 31 participants
Start Date 2019-07-17
Primary Completion 2027-05-17 (estimated)
Study Completion 2027-05-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-05